Rochester Clinical Research

The trials here

What the 22 trials at this site are about, from their registry records.

Conditions

• Obesity9 trials
• Migraine7 trials
• Familial hypercholesterolaemia2 trials
• Type 2 diabetes2 trials
• Ulcerative colitis2 trials
• Atopic dermatitis (eczema)1 trial
• Coeliac disease1 trial
• Coronary artery disease1 trial
• Stroke1 trial

Phase

• Phase 315 trials
• Phase 26 trials
• Phase 11 trial

Status

• Active, not recruiting8 trials
• Completed7 trials
• Recruiting7 trials

Lead sponsor

• Amgen6 trials
• TriGemX Bio, Inc.4 trials
• Abivax S.A.2 trials
• Ipsen2 trials
• Novartis Pharmaceuticals2 trials
• and 6 more

Running trials

• Recruiting

  Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight

  NCT07871409· Phase 3· Amgen· Source

• Recruiting

  A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

  NCT07674654· Phase 3· TriGemX Bio, Inc.· Source

  Contact: Annemarie Vance

• Recruiting

  Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

  NCT07685808· Phase 2· Regeneron Pharmaceuticals· Source

  Contact: Clinical Trials Administrator

• Recruiting

  Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

  NCT07684235· Phase 3· Amgen· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

  NCT07645924· Phase 3· TriGemX Bio, Inc.· Source

  Contact: Annemarie Vance

• Recruiting

  Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

  NCT07575399· Phase 3· Amgen· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Amgen· Source

• Active, not recruiting

  A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

  NCT06965413· Phase 2· Hoffmann-La Roche· Source

• Active, not recruiting

  Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

  NCT06858839· Phase 3· Amgen· Source

• Recruiting

  A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

  NCT06641466· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

  NCT06047444· Phase 3· Ipsen· Source

• Active, not recruiting

  A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

  NCT06047457· Phase 3· Ipsen· Source

• Active, not recruiting

  A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

  NCT05739383· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  ABTECT - Maintenance

  NCT05535946· Phase 3· Abivax S.A.· Source

• Active, not recruiting

  Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

  NCT05030428· Phase 3· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity4 recruiting
• Migraine3 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity

  NCT07310901· Phase 1· Corbus Pharmaceuticals Inc.· Source

• Completed

  A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine

  NCT06848075· Phase 2· TriGemX Bio, Inc.· Source

• Completed

  Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine

  NCT06603623· Phase 2· Biohaven Therapeutics Ltd.· Source

• Completed

  A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833

  NCT06019559· Phase 2· TriGemX Bio, Inc.· Source

• Completed

  A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05704738· Phase 3· Amgen· Source

• Completed

  ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

  NCT05507203· Phase 3· Abivax S.A.· Source

• Completed

  A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

  NCT05353985· Phase 2· Takeda· Source